Added to YB: 2026-01-13
Pitch date: 2026-01-10
ABCL [neutral]
AbCellera Biologics Inc.
-2.38%
current return
Author Info
No bio for this author
Company Info
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Market Cap
$1.3B
Pitch Price
$4.63
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.27
P/E
-7.58
EV/Sales
27.02
Sector
Life Sciences Tools and Services
Category
growth
AbCellera: Mapping the Future of Antibody Drugs.
ABCL (overview): AI-powered antibody discovery platform transitioning from service to clinical-stage developer. $680M liquidity funds ops 3+ years. Pipeline includes ABCL635 (menopause VMS, $2B+ market) & ABCL575 (atopic dermatitis, $11B+ market) with Phase 1 data mid-2026. 103 partner programs, 18 in clinic.
Read full article (9 min)